Clinical Trials

Boston Therapeutics has presented positive results of its PAZ320 drug, designed for reducing post-meal elevation of blood glucose, from its Phase ll clinical trial. Non-systemic chewable complex carbohydrate-based drug is a proprietary polysaccharide which...

Avaxia Biologics has treated the first patient in a Phase1b clinical study using AVX drug dosage, designed for the treatment of ulcerative colitis. The gut-targeted anti-TNF antibody drug is injected into the body to...

CSL Behring has commenced the patient enrollment in pivotal pediatric Phase III hemophilia B study of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP). The study is designed to assess rIX-FP's...

Clinical-stage biotechnology company GlycoMimetics has completed patient enrollment for the Phase 2 sickle cell disease study evaluating GMI-1070. Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics...

Kiadis Pharma has raised EUR10m in a financing round to conduct Phase II study of a cell based medicinal product candidate, ATIR, and to prepare a Phase II/III study. ATIR Phase II study is...

Pfizer Phase III study of pregabalin controlled-release (CR) formulation has met primary endpoint of time to loss of therapeutic response (LTR), in fibromyalgia patients. The primary endpoint of the placebo-controlled, multi-center study was achieved...

Idera Pharmaceuticals has concluded enrolling patients in double-blind, placebo-controlled Phase 2 trial assessing IMO-3100 in psoriasis patients. The study randomized 44 patients suffering from moderate to severe plaque psoriasis with IMO-3100 at 0.16mg/kg or...